Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.
Journal: Case reports in oncology
Published: February 04, 2021
Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.
Journal: Drug design, development and therapy
Published: July 04, 2017
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
Journal: Journal of the National Cancer Institute
Published: February 06, 2017
BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.
BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 23, 2016
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Journal: The Journal of clinical investigation
Published: October 08, 2015
Detection of pars injury by SPECT in patients younger than age 10 with low back pain.
Journal: Journal of pediatric orthopedics
Published: May 09, 2013
Showing 1-6 of 6
Last Updated: 09/26/2026